CMTA is leading a coordinated CMT1A research strategy that connects disease models, drug development, biomarkers, delivery science, and clinical infrastructure to accelerate new treatments.
Leading the Way: The CMTA Invests More Than $200K in Cutting-Edge CMT1A Organoid Research
CMTA announced an investment of more than $200,000 to support CMT1A organoid research, establishing standardized models to evaluate therapies targeting CMT1A.
